A pharmaceutical CEO’s relationship with the board of directors is one of the most consequential dynamics in the company. Board members bring oversight responsibilities, fiduciary duties, and strategic perspectives that shape the organization’s trajectory. Yet the logistics of maintaining that relationship, preparing materials, coordinating schedules, and managing the flow of information fall squarely on the shoulders of the CEO’s personal assistant. In pharma, where board agendas routinely include clinical data updates, regulatory milestone reviews, and pipeline valuations, the PA’s role in board communications is both demanding and specialized.
What Board Communications Actually Involve
Board communications in pharmaceutical companies extend well beyond scheduling quarterly meetings. The PA manages a continuous cycle of information exchange between the CEO, individual board members, the corporate secretary, and external advisors. This includes:
- Coordinating board and committee meeting calendars across multiple time zones
- Preparing and distributing board packets in advance of meetings
- Managing secure document portals (such as Diligent or BoardVantage)
- Tracking action items and following up after each meeting
- Coordinating travel and logistics for in-person board sessions
- Supporting the CEO’s direct communication with individual directors between meetings
Each of these tasks requires attention to confidentiality, timing, and accuracy. A late board packet or a misfiled regulatory update can undermine the CEO’s credibility before a meeting has even begun.
The Board Packet Preparation Process
In pharma, board packets are not simple slide decks. They typically include clinical development updates, safety and adverse event summaries, regulatory timelines, financial performance against plan, commercial launch metrics, and pipeline valuations. The PA must coordinate input from multiple executives including the CFO, Chief Medical Officer, Chief Scientific Officer, and General Counsel, often on a tight deadline.
The process typically runs on a fixed cadence. For a quarterly board meeting, the PA may begin coordinating content collection three to four weeks in advance. She or he sends reminders to each contributing executive, consolidates drafts, flags inconsistencies for the CEO’s review, and manages final formatting and distribution. The PA also ensures that documents transmitted to board members comply with any information barrier policies, particularly important for pharma companies with publicly traded securities and inside information obligations.
Experienced PAs develop templates and timelines that bring structure to what can otherwise become a chaotic content-gathering exercise. A well-managed packet process signals organizational competence to the board before the meeting begins.
Managing the Board Portal
Most pharmaceutical companies of any meaningful size use a secure board portal for document distribution. The PA is typically the primary administrator of this system. Responsibilities include:
- Uploading and organizing documents according to the approved agenda
- Setting access permissions for different board committees (audit, compensation, nominating and governance, science and technology)
- Sending notifications to board members when new materials are posted
- Archiving historical meeting materials in an organized structure
- Troubleshooting access issues for board members, often on tight timelines
The PA also manages the document lifecycle, ensuring that draft materials are clearly labeled, superseded versions are removed, and final approved documents are archived appropriately.
Coordinating Individual Director Communications
Board governance does not happen only in formal meetings. Pharmaceutical CEOs regularly communicate with individual directors between sessions, whether to share a clinical trial readout, discuss an acquisition opportunity, or provide a regulatory update. The PA facilitates this communication by drafting briefing notes, coordinating calls, and ensuring the CEO has relevant context before each director conversation.
The PA maintains a working knowledge of each board member’s background, interests, and communication preferences. A director who is a former FDA Commissioner will have different questions than one who comes from a private equity background. Knowing these distinctions allows the PA to help the CEO tailor communications appropriately.
The PA also tracks which board members have received which communications, maintaining a log that helps the CEO avoid inadvertently sharing material non-public information with some directors and not others.
Supporting Board Committee Work
Pharmaceutical boards typically have several standing committees, each with its own cadence and documentation requirements. The science and technology committee, in particular, is a feature of pharma boards that does not appear in most other industries. This committee reviews clinical development strategy, pipeline prioritization, and research investments.
The CEO’s PA coordinates with the committee chairs and the corporate secretary to ensure that CEO presentations to each committee are appropriately prepared. This may involve coordinating with a different set of executives than those who contribute to the main board packet, such as the Chief Scientific Officer and heads of clinical development.
For pharma companies with an active pipeline, the science committee may meet more frequently than the full board, requiring the PA to manage a more complex calendar of committee meetings alongside the full board schedule.
Handling Confidential and Sensitive Information
Board communications in pharma routinely involve material non-public information: clinical trial results before announcement, pending FDA decisions, acquisition targets under consideration. The PA handling these communications must operate with a high degree of discretion and an understanding of why confidentiality matters.
This is not simply a matter of professional ethics. Improper disclosure of inside information can have legal consequences for the company and individuals involved. A sophisticated PA understands the concept of information barriers, knows which communications must be routed through legal counsel before distribution, and is alert to situations that require escalation.
PAs supporting pharma CEOs in this environment typically receive training on securities law basics, insider trading policies, and the company’s specific confidentiality protocols. They are often required to sign confidentiality agreements that go beyond standard employment terms.
Post-Meeting Follow-Up
A board meeting is not complete when the last slide is presented. The PA plays a critical role in the follow-up process, which typically includes:
- Distributing draft minutes prepared by the corporate secretary for CEO review
- Tracking action items assigned during the meeting
- Following up with executives responsible for delivering on board commitments
- Scheduling any follow-up calls or information requests from board members
- Updating the board calendar for the next cycle of meetings
In pharma, where regulatory timelines and clinical milestones drive much of the board’s agenda, action items often have external deadlines that cannot slip. The PA’s follow-up tracking ensures that the CEO remains accountable to commitments made in the boardroom.
Annual Board Calendar Planning
At the start of each year, the PA works with the corporate secretary and the board chair to establish the calendar for the coming twelve months. This involves identifying available dates across all board members’ schedules, which can be particularly complex when directors include internationally based scientists, investors, or former regulators with demanding travel schedules.
The annual calendar planning process also identifies when key agenda items should be scheduled. In pharma, this means aligning board meeting dates with anticipated clinical readouts, regulatory submission deadlines, and earnings release dates. A board meeting scheduled too close to an FDA action date may require contingency planning if news breaks before the meeting.
The PA maintains this calendar proactively, sending reminders, managing hotel blocks for in-person sessions, and coordinating with venues months in advance.
Skills That Make the Difference
Not every experienced PA is equipped for board communications work at a pharmaceutical company. The skills that distinguish those who thrive in this role include:
Discretion and judgment about what requires CEO attention versus what can be handled independently. Advanced organizational skills, particularly the ability to manage multiple simultaneous workstreams with different owners and deadlines. Strong written communication to draft clear, accurate summaries and briefing notes. Familiarity with pharma industry terminology sufficient to review materials for obvious inconsistencies or errors. Technical comfort with board portal systems and video conferencing platforms used for hybrid board meetings.
PAs who develop deep expertise in board communications often become trusted strategic partners to the CEO, not just logistics coordinators. Their understanding of board dynamics, director preferences, and the flow of corporate governance gives them insights that inform how the CEO manages the board relationship over time.
For more on the full scope of responsibilities that support pharmaceutical executives, see our overview of pharma PA duties. If you are considering the broader PA role for a pharma or biotech CEO, our guide to the pharma CEO assistant provides essential context.
Conclusion
Board communications represent one of the highest-stakes responsibilities a pharmaceutical CEO’s personal assistant will manage. The combination of confidential information, complex logistics, multiple stakeholders, and regulatory sensitivity makes this work genuinely demanding. PAs who approach it with professionalism, discretion, and systematic thinking become indispensable to the CEO’s effectiveness in the boardroom and provide meaningful value to the governance of the organization.
Related Reading
For further context, explore Personal Assistant for 3PL CEO Third Party Logistics: Operational Support for a High-Volume Industry and Personal Assistant for Abrasive Manufacturer CEO.